Sevan acquisisce con sede nel Regno Unito Wyeth Projects Services
Download
September 23, 2020 10:25 AM Eastern Daylight Time
DOWNERS GROVE, Illinois--( BUSINESS WIRE )--Sevan Multi-Site Solutions, Inc. (Sevan), un leader globale di soluzioni innovative per la progettazione, la gestione di programmi, i servizi per l’edilizia e l’analisi di dati, ha acquisito Wyeth Projects Services Ltd. (Wyeth), un’organizzazione con sede nel Regno Unito che fornisce servizi di gestione progetti per gli operatori dei settori petrolio, vendita al dettaglio e ristorazione veloce. L’acquisizione andrà ad espandere la portata globale di Sevan arricchendone il portafoglio clienti. “Siamo molto lieti di accogliere Wyeth in seno alla famiglia Sevan” ha dichiarato Jim Evans, presidente e amministratore delegato di Sevan. “Confidiamo in una transizione agevole e senza intoppi per entrambe le società considerata la forte affinità di valori fondamentali, cultura e pratiche aziendali di Sevan e Wyeth”. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.

Riassunto: Sevan acquisisce con sede nel Regno Unito Wyeth Projects Services

Download
September 23, 2020 09:00 AM Eastern Daylight Time
DOWNERS GROVE, Ill.--( BUSINESS WIRE )--Sevan Multi-Site Solutions, Inc. (Sevan) — a global leader in innovative design, program management, construction services and data analytics — has acquired Wyeth Projects Services Ltd. (Wyeth), a U.K.-based project management services organization serving petroleum, retail and quick-service restaurant clients. The acquisition will add to Sevan’s global footprint and expand the company’s client portfolio. “We are thrilled to welcome Wyeth to the Sevan family,” said Jim Evans, President and CEO of Sevan. “We look forward to a smooth and seamless transition across our companies, as both Sevan’s and Wyeth’s core values, culture and business practices are very similar. Additionally, working alongside Wyeth will further expand the trust of key international clients and accelerate our growth.”
Wyeth — a U.K.-based project management services firm with 20+ employees — was founded in 2009 with a strong reputation for project delivery in the U.K. and globally. Founder Barry Wyeth has grown the business successfully and sees this acquisition as an opportunity to expand into new markets and sectors. “I am extremely excited about this next chapter in the Wyeth story,” said Barry Wyeth. “Together we will provide greater value to our existing clients and expand our client base into new sectors. We share the same values and ambitions to grow and develop in line with Sevan’s vision.”
Founded in 2011, Sevan helps clients develop, refresh and update their portfolio of sites. Large public competitors are not typically focused on the multi-site market, and smaller companies are often unable to compete with the breadth and quality of services Sevan provides. In 2020, Sevan was recognized as an Employee-Rated Great Place to Work® for the 7th consecutive year and ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. In 2018, Great Place to Work® and FORTUNE ranked Sevan No. 29 on the list of 100 Best Medium Workplaces. Visit our website to learn more about Sevan , awards rankings and acquisitions . Sevan is a construction and project management firm that leverages innovative technology to deliver excellence to clients. Sevan is headquartered near Chicago, in Downers Grove, Illinois, with 400+ employees and an international office in London. About Sevan
The vision of Sevan Multi-Site Solutions is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands, including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Chipotle, DaVita, HCA Healthcare, Hallmark, HEB, Jiffy Lube, Kroger, Marathon, McDonald’s, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart and Zaxby’s. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan surveys more than 150 million square feet annually and has licensed architects in 49 states as well as D.C., Canadian provinces, Guam, and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 21,000 retail stores and 14,000 restaurants. Sevan Elevate, a program that reinforces and continuously improves Safety and Sustainability across the company, is designed to impactfully deliver excellence to people and clients. To read more about Sevan, visit www.sevansolutions.com . About Wyeth
Wyeth is a U.K.-based project management services firm founded in 2009 by Barry Wyeth. Wyeth has developed a strong team that works closely with retail and petroleum clients to provide solutions from inception to completion, for their investment and network development goals. The Wyeth team is able to handle a wide range of development and implementation projects from corporate branding programs to new to industry sites. Wyeth always targets the optimum balance of safety, quality, cost and speed. Wyeth works with many global clients including Motor Fuel Group, Valero, Total, Applegreen, Oman Oil, BP and Harvest Energy. As a small company, Wyeth is client-centric, entrepreneurial and solution orientated. To read more about Wyeth, visit www.wyethprojects.com . For more information, please contact Hafsa Mahmood by calling +1 312.285.0590 or via e-mail at hafsa.mahmood@sevansolutions.com .

Sevan Acquires UK-Based Wyeth Projects Services

Recommends Rejection Of Unsolicited Note Tender Offer By Huguenot Bond Liquidity, LLC
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162. Author:
May 22, 2020 4:30 PM EDT
Pfizer Inc. ( PFE ) - Get Report today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162.5 million principal amount of Pfizer's outstanding 7.200% notes due 2039 (the "Pfizer Notes") and up to $130.0 million principal amount of Wyeth's 5.950% notes due 2037 (the "Wyeth Notes" and together with the Pfizer Notes, the "Notes"). Wyeth is a wholly-owned subsidiary of Pfizer. Pfizer and Wyeth do not endorse Offeror's unsolicited tender offer, and neither Pfizer nor Wyeth is affiliated or associated with the Offeror, the tender offer or the offer documentation. The Offeror did not inform Pfizer of the tender offer, and Pfizer only became aware of the offer through a third party source. Further, there is no disclosure of information regarding the Offeror or any indication as to a source of financing for the offer in the offer documentation. Pfizer arrived at this position after considering all of the facts and circumstances surrounding the Offeror's unsolicited tender offer. In particular, Pfizer believes that the tender offer is not in the best interest of the holders of the Notes for the following reasons, among others:
the applicable tender consideration offered by the Offeror, as calculated using a reference date of May 21, 2020, is approximately 7% lower than the last trade price of $166 per $100 principal amount of notes for the Pfizer Notes and approximately 8% lower than the last trade price of $145 per $100 principal amount of notes for the Wyeth Notes, in each case on May 21, 2020, the last business day prior to the issuance of this press release;
the tender consideration is variable and is based on a benchmark security that may trade based on factors independent of those that may affect the trading prices of the Notes; and
the consummation of the offer is subject to a number of conditions and Offeror has retained a right to terminate the tender offer if any of these conditions are not satisfied or, in its absolute discretion, at any time and for any reason, reducing the likelihood that the offer will be consummated. The announcements contained in this press release were made pursuant to Pfizer and Wyeth's obligations under Rule 14e-2 under the Securities Exchange Act of 1934. Pfizer and Wyeth are not taking a position on whether the unsolicited tender offer is being made in accordance with United States federal securities laws, including the applicable rules and regulations issued by the Securities and Exchange Commission. Pfizer urges investors to obtain current market quotations for their Notes, to consult with their broker or financial advisor and to exercise caution with respect to the Offeror's offer. Pfizer recommends that noteholders who have not responded to the Offeror's offer take no action. Holders of Notes who have already tendered their Notes may withdraw them at any time prior to May 26, 2020, in accordance with the Offeror's offering documents. The tender offer is currently scheduled to expire at 5:00 pm New York City time on Tuesday, June 9, 2020. Pfizer requests that a copy of this news release be included with all distributions of materials relating to the Offeror's offer related to the Notes. About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. View source version on businesswire.com: https://www.businesswire.com/news/home/20200522005440/en/
By

Pfizer Inc. Recommends Rejection Of Unsolicited Note Tender Offer By Huguenot Bond Liquidity, LLC

Ping An Good Doctor (HK: 01833) is a healthcare and medical service application offering text, photo, voice, and video consultation for preventive nursery care, guidance for doctor's visits, post-diagnosis services, chronic disease management, medication alerts, and more. Medical experts are available 24/7, communicating with users and providing suggestions based on users' health conditions. Users can purchase medication online in accordance with the advice and have the medication delivered.

Ping An Good Doctor

Ping An Good Doctor and Wyeth partner to bring one-stop nutrition and healthcare solutions

Advanced Life Sciences Holdings is a Healthcare/Biotechnology company based in Woodridge, Illinois. Advanced Life Sciences Holdings' investors include Soros Fund Management, Fort Mason Capital, Tribeca Global Management, Visium Asset Management, JP Morgan Chase & Co, TowerBrook Capital Partners, Cowen Group, Tang Capital Management, Balyasny Asset Management, Xmark Opportunity Partners, MPM Capital, SF Capital Partners, UBS, Morgan Stanley Private Equity, BVF, Nite Capital Management and RA Capital Management.

Advanced Life Sciences Holdings

Print Page Close Window.
Advanced Life Sciences: Advancing Discoveries for Health : Press Release
CHICAGO, Oct. 1 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings,Inc.
Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region.

Progenics Pharmaceuticals develops medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development.

Progenics Pharmaceuticals

Full year 2009 revenues reflect primarily a decrease in reimbursement and milestone revenue from Wyeth , which was offset by recognition in the fourth quarter of the $ 10.0 million termination payment and in the first quarter of 2009 of a $ 15.0 million upfront payment received in 2008 from Ono Pharmaceutical Co. , Ltd. , Progenics Pharmaceuticals , Inc. ' collaborator for subcutaneous RELISTOR in Japan .

Progenics Announces Fourth Quarter and Year-End 2009 Financial Results.

Catalyst Biosciences is developing next generation biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase therapeutics. Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation.

Catalyst Biosciences

Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, global pharmaceutical company.

Takeda Pharmaceutical

NCI Consulting Group

Arno Therapeutics

Merck & Co.

PDL BioPharma

Genetics Institute

Hoffmann-La Roche

Flagship Pioneering

B&C Holding

Semperit

Unilever

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Eno River Capital

Acq - P2P

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Wyeth

Zoetis

Nuron Biotech

Name	Work History	Title	Status
Roger G Berlin	NCI Consulting Group, Arno Therapeutics, and Merck & Co.	President	Former
Leonard Patrick Gage	PDL BioPharma, Genetics Institute, Hoffmann-La Roche, and Flagship Pioneering	President, Senior Vice President	Former
Douglas Rogers		President	Former
Petra Preining	B&C Holding, Semperit, and Unilever	Chief Financial Officer	Former
Frank S Walsh		Executive Vice President	Former

Name	Roger G Berlin	Leonard Patrick Gage	Douglas Rogers	Petra Preining	Frank S Walsh
Work History	NCI Consulting Group, Arno Therapeutics, and Merck & Co.	PDL BioPharma, Genetics Institute, Hoffmann-La Roche, and Flagship Pioneering		B&C Holding, Semperit, and Unilever
Title	President	President, Senior Vice President	President	Chief Financial Officer	Executive Vice President
Status	Former	Former	Former	Former	Former

Wells Fargo Success Story

3M Success Story

Platform Overview

Wyeth

Executives

Wyeth Management Team

10 Team Members

Discover the right solution for your team